XAGE
NASDAQ
US
Longevity Health Holdings, Inc. - Common Stock
$0.28
▼ $-0.01
(-4.10%)
Vol 5K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$536K
ROE
-29.1%
Margin
-683.0%
D/E
5.21
Beta
0.35
52W
$0–$36
Price Chart
Similar Stocks
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -29.1% | -29.1% | -29.1% | -29.1% | -29.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -374.6% | -1534.4% | -683.0% | -683.0% | -683.0% | -683.0% |
| Gross Margin | 60.1% | 56.0% | 57.5% | 57.5% | 57.5% | 57.5% |
| D/E Ratio | — | 5.21 | 5.21 | 5.21 | 5.21 | 5.21 |
| Current Ratio | 0.47 | 0.42 | 0.47 | 0.47 | 0.47 | 0.47 |
Key Ratios
ROA (TTM)
-261.9%
P/S (TTM)
0.51
EPS (TTM)
$-8.52
52W High
$36.00
52W Low
$0.37
$0.37
52-Week Range
$36.00
How does XAGE compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
XAGE valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
0.5
▼
96%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
—
▼
0%
below
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
XAGE profitability vs Biotechnology peers
ROE
-29.1%
▲
57%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-683.0%
▼
138%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
57.5%
▼
27%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-261.9%
▼
461%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
XAGE financial health vs Biotechnology peers
D/E ratio
5.2
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
0.5
▼
89%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.4
▼
64%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
XAGE fundamentals radar
XAGE
Peer median
Industry
XAGE profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
XAGE vs peers: key metrics
Latest News
No related news yet